Repeat hepatectomy for liver metastases from bile duct neuroendocrine tumor: a case report.
Bile duct
Liver metastasis
Neuroendocrine tumor (NET)
Repeat hepatectomy
Journal
Surgical case reports
ISSN: 2198-7793
Titre abrégé: Surg Case Rep
Pays: Germany
ID NLM: 101662125
Informations de publication
Date de publication:
08 Aug 2020
08 Aug 2020
Historique:
received:
30
05
2020
accepted:
29
07
2020
entrez:
10
8
2020
pubmed:
10
8
2020
medline:
10
8
2020
Statut:
epublish
Résumé
Primary neuroendocrine tumor (NET) originating from the extrahepatic bile duct is rare, although liver metastasis from gastroenteropancreatic NET is frequently observed. We herein report a case who successfully underwent repeat hepatectomy for liver metastases from bile duct NET grade 2 (G2). A 75-year-old man presented with jaundice and was suspected of perihilar cholangiocarcinoma by computed tomography (CT) and magnetic resonance imaging (MRI). He underwent extended left hepatectomy, extrahepatic bile duct resection, and hepaticojejunostomy. Pathological findings showed a NET G2 of the biliary tract arising from the common bile duct. Two years and 11 months after surgery, a liver metastasis was detected and hepatectomy was performed. During the surgery, another liver metastasis was detected, and limited liver resection for the two lesions was performed. Pathological findings showed four liver metastases of NET G2. Five years and 4 months after the first surgery (2 years and 5 months after the second hepatectomy), four liver metastases were detected. Thereafter, he received somatostatin analogues for 1 year. Although the size of tumors increased slightly, the number did not change. He underwent limited liver resections and was diagnosed with 7 liver metastases of NET G2. Finally, another hepatectomy (fourth hepatectomy) was performed and long-term survival without recurrence was obtained for as long as 8 years after the first surgery. Repeat hepatectomy is a good option to obtain long-term survival for liver metastases from bile duct NET G2 in select patients.
Sections du résumé
BACKGROUND
BACKGROUND
Primary neuroendocrine tumor (NET) originating from the extrahepatic bile duct is rare, although liver metastasis from gastroenteropancreatic NET is frequently observed. We herein report a case who successfully underwent repeat hepatectomy for liver metastases from bile duct NET grade 2 (G2).
CASE PRESENTATION
METHODS
A 75-year-old man presented with jaundice and was suspected of perihilar cholangiocarcinoma by computed tomography (CT) and magnetic resonance imaging (MRI). He underwent extended left hepatectomy, extrahepatic bile duct resection, and hepaticojejunostomy. Pathological findings showed a NET G2 of the biliary tract arising from the common bile duct. Two years and 11 months after surgery, a liver metastasis was detected and hepatectomy was performed. During the surgery, another liver metastasis was detected, and limited liver resection for the two lesions was performed. Pathological findings showed four liver metastases of NET G2. Five years and 4 months after the first surgery (2 years and 5 months after the second hepatectomy), four liver metastases were detected. Thereafter, he received somatostatin analogues for 1 year. Although the size of tumors increased slightly, the number did not change. He underwent limited liver resections and was diagnosed with 7 liver metastases of NET G2. Finally, another hepatectomy (fourth hepatectomy) was performed and long-term survival without recurrence was obtained for as long as 8 years after the first surgery.
CONCLUSIONS
CONCLUSIONS
Repeat hepatectomy is a good option to obtain long-term survival for liver metastases from bile duct NET G2 in select patients.
Identifiants
pubmed: 32770496
doi: 10.1186/s40792-020-00967-x
pii: 10.1186/s40792-020-00967-x
pmc: PMC7415062
doi:
Types de publication
Journal Article
Langues
eng
Pagination
204Références
HPB (Oxford). 2006;8(1):67-8
pubmed: 18333243
Pathol Oncol Res. 2014 Oct;20(4):765-75
pubmed: 24917351
Hepatobiliary Pancreat Dis Int. 2009 Dec;8(6):640-6
pubmed: 20007084
Hepatogastroenterology. 2004 Sep-Oct;51(59):1295-300
pubmed: 15362737
Gastroenterology. 1984 May;86(5 Pt 1):892-6
pubmed: 6142846
Mod Pathol. 2011 Apr;24 Suppl 2:S53-7
pubmed: 21455201
Lancet Oncol. 2014 Jan;15(1):e8-21
pubmed: 24384494
Zentralbl Chir. 1987;112(18):1170-5
pubmed: 3687265
Endocr Relat Cancer. 2011 Oct 17;18 Suppl 1:S1-16
pubmed: 22005112
Int J Surg Case Rep. 2017;40:6-9
pubmed: 28915429
Am J Clin Pathol. 1976 Jul;66(1):40-5
pubmed: 59542
Cancer. 1999 Nov 15;86(10):1959-65
pubmed: 10570419
Surgery. 2011 Feb;149(2):209-20
pubmed: 20674950
J Am Coll Surg. 2007 Aug;205(2):357-61
pubmed: 17660084
Cancer. 1975 Aug;36(2):560-9
pubmed: 1157019
HPB Surg. 1996;10(1):41-3
pubmed: 9187551
Cancer. 2003 Feb 15;97(4):934-59
pubmed: 12569593
Nihon Shokakibyo Gakkai Zasshi. 2006 Oct;103(10):1169-75
pubmed: 17023761
Ann Oncol. 2010 Oct;21 Suppl 7:vii72-80
pubmed: 20943646
Scand J Gastroenterol. 2016;51(5):513-23
pubmed: 26605828
Am J Gastroenterol. 1991 Aug;86(8):1073-6
pubmed: 1858744
Ann Diagn Pathol. 2009 Dec;13(6):378-83
pubmed: 19917473
J Natl Compr Canc Netw. 2012 Jun 1;10(6):724-64
pubmed: 22679117
Ann Surg Oncol. 2017 Aug;24(8):2319-2325
pubmed: 28303430
Surg Today. 1998;28(11):1192-5
pubmed: 9851632
Abdom Imaging. 1993;18(3):242-4
pubmed: 8508084
Hum Pathol. 2004 Dec;35(12):1440-51
pubmed: 15619202